Lipid nanoparticles for chemotherapeutic applications: Strategies to improve anticancer efficacy

Expert Opinion on Drug Delivery

Volumn 9, Issue 7, 2012, Pages 767-781

  Lin, Xia ^a   Gao, Renchao ^a   Zhang, Yan ^a   Qi, Na ^a   Zhang, Yu ^a   Zhang, Keru ^a   He, Haibing ^a   Tang, Xing ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

anticancer drug delivery; enhanced anticancer efficacy; nanostructured lipid carriers; solid lipid nanoparticles

Indexed keywords

ALPHA TOCOTRIENOL; CAMPTOTHECIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; ELACRIDAR; FLUOROURACIL; FOLIC ACID; LIPID NANOPARTICLE; MACROGOL; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; NANOSTRUCTURED LIPID CARRIER; OCTADECYLAMINE; OCTREOTIDE; PACLITAXEL; PHENETHYL ISOTHIOCYANATE; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER TISSUE; CONTROLLED RELEASE FORMULATION; CYTOTOXICITY; DNA DAMAGE; DRUG DELIVERY SYSTEM; DRUG DETOXIFICATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG STABILITY; DRUG TOLERABILITY; DRUG TRANSPORT; ENCAPSULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENETIC THERAPY; HUMANS; LIPIDS; NANOPARTICLES; NEOPLASMS;

EID: 84862740863     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.685933     Document Type: Review

References (98)

1. Boyle P, Levin B. editors. Worldwide cancer burden. In: World Cancer Report 2008. International Agency for Research on Cancer; Lyon, France: 2008. p. 42-56
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
3. Roland TS. editor. Selection of treatment for the patient with cancer. In: Handbook of Cancer Chemotherapy. Lippincott Williams & Wilkins Press; Philadeiphia, USA: 2007. p. 47-52
4. Boyle P, Levin B editors. Principles of cancer therapy: medical oncology. In: World Cancer Report 2008. International Agency for Research on Cancer; Lyon, France: 2008. p. 62-7
5. Roland TS, Samir NK. Biologic and pharmacologic basis of cancer chemotherapy and biotherapy. In: Roland TS, editor. Handbook of Cancer Chemotherapy. Lippincott Williams & Wilkins Press; Philadeiphia, USA: 2007. p. 1-31
6. Feng S-S, Chien S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Eng Sci 2003;58:4087-114 (Pubitemid 37164365)
7. Joshi MD, Muller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009;71:161-72
8. Ho Lun W, Xiao Yu W, Reina B, et al. editors. Solid lipid nanoparticles for anti-tumor drug delivery. In: Nanotechnology for Cancer Therapy. CRC Press; Florida, USA; 2006. p. 741-76
9. Marcucci F, Corti A. How to improve exposure of tumor cells to drugs - Promoter drugs increase tumor uptake and penetration of effector drugs. Adv Drug Deliv Rev 2011;published online 28 September 2011; doi:10.1016/j.addr.2011.09. 007
10. Jang SH, Wientjes MG, Lu D, et al. Drug delivery and transport to solid tumors. Pharm Res 2003;20:1337-50 (Pubitemid 37164040)
11. Padera TP, Stoll BR, Tooredman JB, et al. Pathology: cancer cells compress intratumour vessels. Nature 2004;427:695 (Pubitemid 38294577)
12. Ahlstrom H, Christofferson R, Lorelius LE. Vascularization of the continuous human colonic cancer cell line LS 174 T deposited subcutaneously in nude rats. APMIS 1988;96:701-10
13. Iyer AK, Khaled G, Fang J, et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006;11:812-18 (Pubitemid 44280021)
14. Sim H, Bibee K, Wickline S, et al. Pharmacokinetic modeling of tumor bioluminescence implicates efflux, and not influx, as the bigger hurdle in cancer drug therapy. Cancer Res 2011;71:686-92
15. Heldin CH, Rubin K, Pietras K, et al. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13 (Pubitemid 39331152)
16. Netti PA, Berk DA, Swartz MA, et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000;60:2497-503 (Pubitemid 30262444)
17. Primeau AJ, Rendon A, Hedley D, et al. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005;11:8782-8 (Pubitemid 43005929)
18. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970;30:1174-84
19. Gouaze V, Yu JY, Bleicher RJ, et al. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther 2004;3:633-9 (Pubitemid 39193742)
20. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34 (Pubitemid 43336035)
21. Gong J, Jaiswal R, Mathys JM, et al. Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat Rev 2011;published online 14 July 2011; doi:10.1016/j.bbr.2011.03.031
22. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27 (Pubitemid 34177898)
23. Ak Y, Demirel G, Gulbas Z. MDR1, MRP1 and LRP expression in patients with untreated acute leukaemia: correlation with 99mTc-MIBI bone marrow scintigraphy. Nucl Med Commun 2007;28:541-6 (Pubitemid 46848646)
24. Schimmel KJ, Richel DJ, van den Brink RB, et al. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004;30:181-91 (Pubitemid 38418056)
25. Pazdur R, Kudelka AP, Kavanagh JJ, et al. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993;19:351-86 (Pubitemid 23333409)
26. Cavalli R, Caputo O, Gasco MR. Solid lipospheres of doxorubicin and idarubicin. Int J Pharm 1993;89:R9-R12 (Pubitemid 23008586)
27. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257-72 (Pubitemid 38510473)
28. Olbrich C, Gessner A, Kayser O, et al. Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target 2002;10:387-96
29. Li Y, Taulier N, Rauth AM, et al. Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN). Pharm Res 2006;23:1877-87 (Pubitemid 44200552)
30. Wong HL, Bendayan R, Rauth AM, et al. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci 2004;93:1993-2008 (Pubitemid 39045481)
31. Wang JX, Sun X, Zhang ZR. Enhanced brain targeting by synthesis of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm 2002;54:285-90 (Pubitemid 35341828)
32. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002;54(Suppl 1):S131-55 (Pubitemid 35379959)
33. Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002;242:121-8
34. Zhang XG, Miao J, Dai YQ, et al. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm 2008;361:239-44 This report developed cytotoxic drug-loaded NLCs to overcome MDR.
35. Arias JL, Clares B, Morales ME, et al. Lipid-based drug delivery systems for cancer treatment. Curr Drug Targets 2011;12:1151-65
36. Irache JM, Esparza I, Gamazo C, et al. Nanomedicine: novel approaches in human and veterinary therapeutics. Vet Parasitol 2011;180:47-71
37. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010;148:135-46
38. Ali H, Shirode AB, Sylvester PW, et al. Preparation and in vitro antiproliferative effect of tocotrienol loaded lipid nanoparticles. Colloid Surf A 2010;353:43-51
39. Liu D, Liu Z, Wang L, et al. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloid Surf B 2011;85:262-9 The first report about docetaxel-NLC for mice-bearing murine malignant melanoma treatment.
40. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55:3752-6
41. Zara GP, Cavalli R, Fundaro A, et al. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol Res 1999;40:281-6 (Pubitemid 29435729)
42. Yang SC, Lu LF, Cai Y, et al. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 1999;59:299-307 (Pubitemid 29238174)
43. Yang S, Zhu J, Lu Y, et al. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999;16:751-7 (Pubitemid 29227107)
44. Blasi P, Giovagnoli S, Schoubben A, et al. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 2007;59:454-77 A review describes the use of SLNs for brain targeting. (Pubitemid 47259226)
45. Kaur IP, Bhandari R, Bhandari S, et al. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008;127:97-109 A review discusses the use of SLNs for brain targeting.
46. Tsai MJ, Wu PC, Huang YB, et al. Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. Int J Pharm 2012;423:461-70
47. Fundaro A, Cavalli R, Bargoni A, et al. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 2000;42:337-43
48. Kabanov AV, Batrakova EV, Miller DW. Pluronic® block copolymers as modulators of drug efflux transporter activity in the blood--brain barrier. Adv Drug Deliv Rev 2003;55:151-64 A paper describes the application of Pluronic for inhibiting P-gp. (Pubitemid 36078456)
49. Koziara JM, Lockman PR, Allen DD, et al. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 2004;99:259-69 The paper describes the application of SLNs for enhancing the brain uptake of drug. (Pubitemid 39222111)
50. Goppert TM, Muller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J Drug Target 2005;13:179-87 (Pubitemid 40668171)
51. Koziara JM, Lockman PR, Allen DD, et al. In situ blood-brain barrier transport of nanoparticles. Pharm Res 2003;20:1772-8 (Pubitemid 37449450)
52. Reddy LH, Sharma RK, Chuttani K, et al. Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies. AAPS J 2004;6:e23
53. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 2005;107:215-28 (Pubitemid 41319672)
54. Harivardhan Reddy L, Sharma RK, Chuttani K, et al. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J Control Release 2005;105:185-98 (Pubitemid 40941985)
55. Wen CJ, Yen TC, Al-Suwayeh SA, et al. In vivo real-time fluorescence visualization and brain-targeting mechanisms of lipid nanocarriers with different fatty ester:oil ratios. Nanomedicine (Lond) 2011;6:1545-59
56. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nano 2007;2:751-60 (Pubitemid 350223348)
57. Lu Y, Low PS. Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects. J Control Release 2003;91:17-29 (Pubitemid 37303991)
58. Stevens PJ, Sekido M, Lee RJ. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm Res 2004;21:2153-7 (Pubitemid 40568428)
59. Stevens PJ, Sekido M, Lee RJ. Synthesis and evaluation of a hematoporphyrin derivative in a folate receptor-targeted solid-lipid nanoparticle formulation. Anticancer Res 2004;24:161-5 (Pubitemid 38279703)
60. Hogemann-Savellano D, Bos E, Blondet C, et al. The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 2003;5:495-506 (Pubitemid 38045087)
61. Jain SK, Chaurasiya A, Gupta Y, et al. Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J Microencapsul 2008;25:289-97 A paper describes a active-targeting SLNs using ferritin as ligand. (Pubitemid 352025005)
62. Wong HL, Bendayan R, Rauth AM, et al. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007;59:491-504 (Pubitemid 47259227)
63. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003;42:463-78 (Pubitemid 37237636)
64. Chen DB, Yang TZ, Lu WL, et al. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull 2001;49:1444-7
65. Zara GP, Cavalli R, Bargoni A, et al. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target 2002;10:327-35 (Pubitemid 34746314)
66. Reddy LH, Vivek K, Bakshi N, et al. Tamoxifen citrate loaded solid lipid nanoparticles (SLN): preparation, characterization, in vitro drug release, and pharmacokinetic evaluation. Pharm Dev Technol 2006;11:167-77 (Pubitemid 43879940)
67. Zhao X, Zhao Y, Geng L, et al. Pharmacokinetics and tissue distribution of docetaxel by liquid chromatography-mass spectrometry: evaluation of folate receptor-targeting amphiphilic copolymer modified nanostructured lipid carrier. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:3721-7 A paper describes the pharmacokinetics and tissue distribution of active ligand-conjugated stealth NLCs.
68. Su Z, Niu J, Xiao Y, et al. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine. Mol Pharm 2011;8:1641-51 A paper on octreotide-PEG-modified NLCs with long circulating and active targeting effects.
69. Lamberts SW, de Herder WW, Hofland LJ. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab 2002;13:451-7 (Pubitemid 36733940)
70. Fang C, Shi B, Pei YY, et al. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci 2006;27:27-36 (Pubitemid 41728252)
71. Hu Y, Xie J, Tong YW, et al. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J Control Release 2007;118:7-17 (Pubitemid 46283099)
72. Xue HY, Wong HL. Solid lipid-PEI hybrid nanocarrier: an integrated approach to provide extended, targeted, and safer siRNA therapy of prostate cancer in an all-in-one manner. ACS Nano 2011;5:7034-47 This paper describes the use of LPNs for delivering siRNA in an all-in-one manner.
73. Wong HL, Rauth AM, Bendayan R, et al. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res 2006;23:1574-85 (Pubitemid 43993820)
74. Wong HL, Bendayan R, Rauth AM, et al. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther 2006;317:1372-81 (Pubitemid 43764144)
75. Ma P, Dong X, Swadley CL, et al. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J Biomed Nanotechnol 2009;5:151-61 A paper describes a doxorubicin SLN that can overcome Pgp-mediated MDR both in vitro and in vivo.
76. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004;56:1649-59 (Pubitemid 39177694)
77. Miglietta A, Cavalli R, Bocca C, et al. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm 2000;210:61-7 This paper addresses the mechanism of MDR reversal activity of drug-loaded SLNs. (Pubitemid 32332642)
78. Serpe L, Catalano MG, Cavalli R, et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 2004;58:673-80 (Pubitemid 39297116)
79. Bogman K, Erne-Brand F, Alsenz J, et al. The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J Pharm Sci 2003;92:1250-61 (Pubitemid 36676470)
80. Alakhov V, Moskaleva E, Batrakova EV, et al. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug Chem 1996;7:209-16
81. Venne A, Li S, Mandeville R, et al. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 1996;56:3626-9 (Pubitemid 26272000)
82. Batrakova EV, Li S, Elmquist WF, et al. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br J Cancer 2001;85:1987-97 (Pubitemid 34775338)
83. Batrakova E, Lee S, Li S, et al. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm Res 1999;16:1373-9 (Pubitemid 29449373)
84. Dong X, Mattingly CA, Tseng MT, et al. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 2009;69:3918-26 This paper describes the role of a P-gp reversing surfactant, Brij 78, in LNs.
85. Wong HL, Bendayan R, Rauth AM, et al. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release 2006;116:275-84 (Pubitemid 44827405)
86. Ying X-Y, Cui D, Yu L, et al. Solid lipid nanoparticles modified with chitosan oligosaccharides for the controlled release of doxorubicin. Carbohydr Polym 2011;84:1357-64
87. Dharmala K, Yoo JW, Lee CH. Development of chitosan-SLN microparticles for chemotherapy: in vitro approach through efflux-transporter modulation. J Control Release 2008;131:190-7
88. Liu YY, Han TY, Giuliano AE, et al. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 1999;274:1140-6
89. Liu YY, Han TY, Yu JY, et al. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells. J Lipid Res 2004;45:933-40 (Pubitemid 38552864)
90. Siddiqui A, Patwardhan GA, Liu YY, et al. Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells. Int J Pharm 2010;400:251-9
91. Bondi ML, Craparo EF. Solid lipid nanoparticles for applications in gene therapy: a review of the state of the art. Expert Opin Drug Deliv 2010;7:7-18 A good review on the applications of SLNs in gene therapy.
92. Tseng YC, Mozumdar S, Huang L. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev 2009;61:721-31
93. del Pozo-Rodriguez A, Delgado D, Solinis MA, et al. Solid lipid nanoparticles as potential tools for gene therapy: In vivo protein expression after intravenous administration. Int J Pharm 2010;385:157-62
94. Choi SH, Jin SE, Lee MK, et al. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur J Pharm Biopharm 2008;68:545-54 (Pubitemid 351318200)
95. Yu YH, Kim E, Park DE, et al. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur J Pharm Biopharm 2012;80:268-73
96. Vighi E, Ruozi B, Montanari M, et al. pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles. Int J Pharm 2010;389:254-61
97. del Pozo-Rodriguez A, Solinis MA, Gascon AR, et al. Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur J Pharm Biopharm 2009;71:181-9
98. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/ Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-9 (Pubitemid 38444547)